Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CDNA

CDNA - CareDx Inc Stock Price, Fair Value and News

18.10USD-0.04 (-0.22%)Market Closed

Market Summary

CDNA
USD18.10-0.04
Market Closed
-0.22%

CDNA Stock Price

View Fullscreen

CDNA RSI Chart

CDNA Valuation

Market Cap

942.7M

Price/Earnings (Trailing)

-5.15

Price/Sales (Trailing)

3.43

EV/EBITDA

-5.04

Price/Free Cashflow

-27.43

CDNA Price/Sales (Trailing)

CDNA Profitability

Operating Margin

81.23%

EBT Margin

-66.61%

Return on Equity

-71.5%

Return on Assets

-40.49%

Free Cashflow Yield

-3.65%

CDNA Fundamentals

CDNA Revenue

Revenue (TTM)

275.1M

Rev. Growth (Yr)

-6.75%

Rev. Growth (Qtr)

9.88%

CDNA Earnings

Earnings (TTM)

-183.2M

Earnings Growth (Yr)

29.85%

Earnings Growth (Qtr)

85.89%

Breaking Down CDNA Revenue

Last 7 days

13.8%

Last 30 days

28.6%

Last 90 days

117.8%

Trailing 12 Months

80.5%

How does CDNA drawdown profile look like?

CDNA Financial Health

Current Ratio

4.32

CDNA Investor Care

Buy Backs (1Y)

3.18%

Diluted EPS (TTM)

-3.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024275.1M000
2023319.6M309.3M297.1M280.3M
2022308.4M314.9M318.6M321.8M
2021221.2M253.6M275.8M296.4M
2020139.5M149.8M169.4M192.2M
201988.5M102.1M114.8M127.1M
201850.8M56.6M65.6M76.6M
201745.7M47.0M46.7M48.3M
201627.5M31.1M36.4M40.6M
201528.6M29.0M29.4M28.1M
201423.0M24.4M25.2M27.3M
201320.9M21.3M21.7M22.1M
201200020.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of CareDx Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 08, 2024
goldberg michael
acquired
-
-
2,963
-
Jul 08, 2024
maag peter
acquired
-
-
1,034
-
Jul 08, 2024
johnson alexander l
sold (taxes)
-9,884
15.59
-634
see remarks
Jul 08, 2024
novack jeffrey adam
sold (taxes)
-2,852
15.59
-183
secretary and general counsel
Jun 17, 2024
johnson alexander l
sold (taxes)
-125,286
13.54
-9,253
see remarks
Jun 14, 2024
hagstrom william a
acquired
-
-
10,570
-
Jun 14, 2024
maag peter
acquired
-
-
10,570
-
Jun 14, 2024
goldberg michael
acquired
-
-
10,570
-
Jun 14, 2024
riggsbee richard bryan
acquired
-
-
10,570
-
Jun 14, 2024
valantine hannah
acquired
-
-
10,570
-

1–10 of 50

Which funds bought or sold CDNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
reduced
-2.71
228,491
763,890
-%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
reduced
-55.21
-171,595
328,444
-%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
0.18
32,360
101,333
-%
Jul 19, 2024
HARBOR INVESTMENT ADVISORY, LLC
unchanged
-
1,976
6,212
-%
Jul 19, 2024
Sumitomo Mitsui Trust Holdings, Inc.
reduced
-6.26
10,904,400
40,009,300
0.03%
Jul 18, 2024
Blue Trust, Inc.
new
-
138
138
-%
Jul 18, 2024
Assenagon Asset Management S.A.
reduced
-53.36
-1,193,390
2,582,720
0.01%
Jul 17, 2024
ARS Investment Partners, LLC
reduced
-39.28
-155,539
1,264,690
0.12%
Jul 12, 2024
SG Americas Securities, LLC
added
900
1,598,000
1,715,000
0.01%
Jul 10, 2024
CWM, LLC
reduced
-20.5
3,000
18,000
-%

1–10 of 47

Are Funds Buying or Selling CDNA?

Are funds buying CDNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CDNA
No. of Funds

Unveiling CareDx Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
arrowmark colorado holdings llc
0%
0
SC 13G/A
Feb 13, 2024
bellevue asset management (uk) ltd.
7.3%
3,954,792
SC 13G/A
Feb 13, 2024
gagnon securities llc
4.7%
2,518,484
SC 13G/A
Feb 13, 2024
vanguard group inc
7.62%
4,119,682
SC 13G/A
Feb 12, 2024
nikko asset management americas, inc.
5.31%
2,874,899
SC 13G
Feb 05, 2024
sumitomo mitsui trust holdings, inc.
5.31%
2,874,899
SC 13G
Jan 29, 2024
ark investment management llc
13.30%
7,194,722
SC 13G/A
Jan 24, 2024
blackrock inc.
10.2%
5,543,666
SC 13G/A
Jan 10, 2024
state street corp
5.17%
2,796,267
SC 13G/A
Jul 07, 2023
blackrock inc.
10.1%
5,439,512
SC 13G/A

Recent SEC filings of CareDx Inc

View All Filings
Date Filed Form Type Document
Jul 10, 2024
4
Insider Trading
Jul 10, 2024
4
Insider Trading
Jul 10, 2024
4
Insider Trading
Jul 10, 2024
4
Insider Trading
Jul 08, 2024
4
Insider Trading
Jun 24, 2024
4/A
Insider Trading
Jun 21, 2024
S-8
Employee Benefits Plan
Jun 20, 2024
4/A
Insider Trading
Jun 20, 2024
4/A
Insider Trading
Jun 20, 2024
4/A
Insider Trading

Peers (Alternatives to CareDx Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.4B
23.7B
-5.41% 12.43%
40.98
7.6
-8.94% -35.91%
38.7B
3.7B
-7.03% -13.75%
44.62
10.38
8.57% 23.94%
38.5B
6.6B
-2.30% 5.82%
30.96
5.83
-6.38% -8.07%
16.2B
9.3B
6.34% 1.67%
19.17
1.75
-3.29% 6.68%
13.0B
2.0B
4.50% 70.57%
41.75
6.65
25.57% 21.62%
13.0B
1.2B
-1.84% 123.25%
-35.62
10.77
39.26% 33.08%
11.2B
4.1B
4.05% 7.02%
25.3
2.73
0.49% -10.45%
MID-CAP
8.6B
2.5B
11.64% -50.70%
-35.95
3.41
15.21% 53.51%
3.8B
603.7M
2.74% -17.56%
-8.17
6.23
25.21% 30.68%
3.5B
929.2M
-2.97% -26.96%
2.3K
3.81
28.93% 111.61%
SMALL-CAP
942.7M
275.1M
28.64% 80.46%
-5.15
3.43
-13.93% -126.97%
94.1M
31.1M
16.81% -87.36%
-1.22
3.02
0.95% 19.75%
18.8M
9.0M
-7.93% -45.09%
-1.28
2.09
4.46% 45.80%
393.9K
5.5M
-13.04% -71.63%
-0.03
0.07
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

CareDx Inc News

Latest updates
MarketBeat33 hours ago
Defense World18 Jul 202411:14 am
MarketBeat17 Jul 202409:48 pm
StockTitan16 Jul 202411:11 am
Seeking Alpha15 Jul 202405:01 pm

CareDx Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue9.9%72,049,00065,569,00067,192,00070,301,00077,262,00082,384,00079,359,00080,634,00079,416,00079,220,00075,589,00074,188,00067,400,00058,644,00053,369,00041,801,00038,380,00035,821,00033,811,00031,454,00025,982,000
Cost Of Revenue----------------15,025,00012,392,00012,716,00011,494,00011,512,0009,733,000
Gross Profit----------------26,776,00025,988,00023,105,00022,317,00019,942,00016,249,000
Operating Expenses-51.4%91,386,000188,201,00095,975,00097,925,000101,586,000101,504,00096,698,000102,353,00098,469,00094,619,00084,316,00078,930,00068,258,00061,711,00056,276,00052,604,00044,131,00051,988,50040,558,00026,786,00021,645,000
  S&GA Expenses-0.8%19,830,00019,999,00018,474,00021,630,00023,231,00023,668,00022,261,00026,950,00023,148,00020,824,00021,370,00019,599,00015,452,00016,131,00013,870,00012,134,00011,723,00010,267,00011,058,00010,644,0006,925,000
  R&D Expenses2.4%18,711,00018,276,00019,000,00020,233,00024,357,00023,570,00022,306,00022,632,00021,880,00022,046,00019,439,00019,036,00016,004,00013,325,00012,474,00013,129,00010,013,0008,946,0008,521,0007,630,0005,614,000
EBITDA Margin2.3%-0.61-0.63-0.26-0.23-0.21-0.20-0.20-0.19-0.13-0.08-0.04-0.01-0.03--------
Income Taxes-146.9%-83,000177,000-80,000-68,000100,000173,000267,000-49,000-12,000-876,000-200,000-100,000-300,000-168,500-235,000-300,000-300,000-238,500-900,000-200,000-606,000
Earnings Before Taxes85.8%-16,742,000-117,932,000-23,565,000-25,021,000-23,625,000-18,156,000-16,672,000-21,746,000-19,660,000-17,052,000-12,059,000-2,027,000-950,000-3,686,000-3,053,000-6,888,000-6,123,000-4,981,000-2,762,000-8,067,000-8,137,000
EBT Margin1.8%-0.67-0.68-0.30-0.27-0.25-0.24-0.24-0.22-0.16-0.11-0.07-0.04-0.07--------
Net Income85.9%-16,659,000-118,097,000-23,485,000-24,953,000-23,749,000-18,329,000-16,939,000-21,697,000-19,648,000-16,151,000-11,897,000-1,927,000-687,000-3,515,000-2,818,000-6,558,000-5,823,000-4,777,000-1,813,000-7,847,000-7,531,000
Net Income Margin1.9%-0.67-0.68-0.30-0.27-0.25-0.24-0.23-0.22-0.16-0.10-0.07-0.04-0.06--------
Free Cashflow-82.7%-15,312,000-8,381,000-13,802,000-4,122,000-2,952,0003,562,000-10,702,000-7,500,000-25,091,000543,000-3,241,0006,950,000-34,880,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-3.1%452467501515528543545541547567563557541369354345157152145143128
  Current Assets-3.4%30331434536137138838840441143344544143927325925266.0072.0068.0068.0078.00
    Cash Equivalents13.5%93.0082.0076.0088.0075.0090.0083.0016717234835333630913521421132.0038.0041.0044.0058.00
  Inventory3.4%20.0019.0018.0019.0018.0019.0018.0019.0018.0017.0019.0015.0014.0010.0010.009.007.006.006.005.005.00
  Net PPE-2.4%34.0035.00--------19.0014.0011.0011.0010.007.006.004.004.004.004.00
  Goodwill0%40.0040.0040.0040.0040.0038.0038.0037.0037.0037.0026.0026.0026.0024.0024.0024.0024.0024.0024.00--
Liabilities-4.5%19620510711010811210898.0089.0010191.0078.0070.0091.0085.0084.0055.0053.0047.0050.0032.00
  Current Liabilities-10.1%70.0078.0073.0074.0072.0076.0070.0078.0067.0077.0070.0056.0046.0069.0062.0057.0028.0035.0031.0029.0016.00
Shareholder's Equity-2.0%25626139440542043143744445846647248047227826926110199.0098.0093.0096.00
  Retained Earnings-2.5%-695-678-534-509-484-460-441-424-402-383-367-355-353-352-349-346-339-333-329-327-319
  Additional Paid-In Capital1.4%960947937924912899887875865854843838828632622612448438432425420
Shares Outstanding0.5%52.0052.0054.0054.0054.0054.0053.0053.0053.0052.0052.0052.00---------
Float----437---1,100---4,600---1,700---1,502-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-82.7%-15,312-8,381-10,179-4996717,185-7,079-3,877-21,4684,1663829,788-33,6307,1815,20724,098-3,055-1,0836053,576-5,867
  Share Based Compensation34.0%13,3449,96112,67112,70013,75412,12611,20012,59310,6349,49810,6389,3986,5475,9776,7486,4174,2595,4075,9654,9926,053
Cashflow From Investing-33.1%27,66041,367-1,49815,348-14,7712,475-75,735790-156,032-7,78220,20216,21319,079-90,474-4,236-3,980-1,704-1,342-3,515-17,179-543
Cashflow From Financing95.3%-1,275-26,877-25.00-1,566-1,138-2,372-1,031-1,997865-834-3,133381189,2283,9641,224158,696-73582.00746-272-688
  Buy Backs-98.0%52225,97081467.00690642--------698-------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CDNA Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 72,049$ 77,262
Operating expenses:  
Research and development18,71124,357
Sales and marketing19,83023,231
General and administrative26,91128,032
Total operating expenses91,386101,586
Loss from operations(19,337)(24,324)
Other income:  
Interest income, net2,8852,666
Change in estimated fair value of common stock warrant liability07
Other expense, net(290)(1,974)
Total other income2,595699
Loss before income taxes(16,742)(23,625)
Income tax benefit (expense)83(124)
Net loss$ (16,659)$ (23,749)
Net loss per share  
Basic (in dollars per share)$ (0.32)$ (0.44)
Diluted (in dollars per share)$ (0.32)$ (0.44)
Weighted-average shares used to compute net loss per share:  
Basic (in shares)51,692,35853,643,216
Diluted (in shares)51,692,35853,643,216
Testing services revenue  
Revenue:  
Total revenue$ 53,837$ 61,784
Operating expenses:  
Cost of testing services, product, digital, and other13,63215,296
Product revenue  
Revenue:  
Total revenue8,5946,861
Operating expenses:  
Cost of testing services, product, digital, and other5,3444,066
Patient and digital solutions revenue  
Revenue:  
Total revenue9,6188,617
Operating expenses:  
Cost of testing services, product, digital, and other$ 6,958$ 6,604

CDNA Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 93,299$ 82,197
Marketable securities122,622153,221
Accounts receivable60,14951,061
Inventory20,13019,471
Prepaid and other current assets6,8957,763
Total current assets303,095313,713
Property and equipment, net34,41135,246
Operating leases right-of-use assets28,59129,891
Intangible assets, net43,33045,701
Goodwill40,33640,336
Restricted cash583586
Other assets2,0601,353
Total assets452,406466,826
Current liabilities:  
Accounts payable9,97612,872
Accrued compensation14,56519,703
Accrued and other liabilities45,67045,497
Total current liabilities70,21178,072
Deferred tax liability43136
Deferred payments for intangible assets1,3482,461
Operating lease liability, less current portion26,89328,278
Other liabilities97,68696,551
Total liabilities196,181205,498
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock: $0.001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock: $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 51,782,612 and 51,503,377 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively4949
Additional paid-in capital959,734946,511
Accumulated other comprehensive loss(8,108)(6,963)
Accumulated deficit(695,450)(678,269)
Total stockholders’ equity256,225261,328
Total liabilities and stockholders’ equity$ 452,406$ 466,826
CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEcaredx.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES727

CareDx Inc Frequently Asked Questions


What is the ticker symbol for CareDx Inc? What does CDNA stand for in stocks?

CDNA is the stock ticker symbol of CareDx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CareDx Inc (CDNA)?

As of Fri Jul 19 2024, market cap of CareDx Inc is 942.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDNA stock?

You can check CDNA's fair value in chart for subscribers.

What is the fair value of CDNA stock?

You can check CDNA's fair value in chart for subscribers. The fair value of CareDx Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CareDx Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CareDx Inc a good stock to buy?

The fair value guage provides a quick view whether CDNA is over valued or under valued. Whether CareDx Inc is cheap or expensive depends on the assumptions which impact CareDx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDNA.

What is CareDx Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, CDNA's PE ratio (Price to Earnings) is -5.15 and Price to Sales (PS) ratio is 3.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDNA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CareDx Inc's stock?

In the past 10 years, CareDx Inc has provided 0.061 (multiply by 100 for percentage) rate of return.